Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 89, Issue 2, 2014, Pages 207-216

  Colombo, Pierre Emmanuel ^a   Fabbro, Michel ^a   Theillet, Charles ^b   Bibeau, Frédéric ^a   Rouanet, Philippe ^a   Ray Coquard, Isabelle ^c  

^a CENTRE VAL D AURELLE   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

DNA repair pathways; Heterogeneity; Molecular subtypes; Ovarian cancer; Resistance

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; OLAPARIB; PACLITAXEL; TOPOTECAN; TRABECTEDIN;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CHEMOSENSITIVITY; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; MOLECULAR MECHANICS; OVARY CARCINOMA; RECURRENT DISEASE; REVIEW; THERAPY RESISTANCE;

AMERICAN SOCIETY OF CLINICAL ONCOLOGY; ARID1A; ASCO; AT-RICH INTERACTIVE DOMAIN 1A GENE; ATAXIA TELANGIECTASIA AND RAD3 RELATED; ATAXIA TELANGIECTASIA MUTATED; ATM; ATR; B-RAF; BASE EXCISION REPAIR; BER; BRCA1/2; BREAST CANCER GENE 1 OR 2; CCNE1; COPPER TRANSPORTER 1; CTR1; CYCLIN E1; DNA REPAIR PATHWAYS; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERCC1; EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1; FANCD2; FANCONI ANAEMIA, COMPLEMENTATION GROUP D2; FIGO; GASTRO-INTESTINAL STROMAL TUMOUR; GIST; GLUTHATIONE S-TRANSFERASE; GST; HER2; HETEROGENEITY; HOMOLOGOUS RECOMBINATION; HR; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2; INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS; K-RAS; MAPK; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR SUBTYPES; MRP2; MULTIDRUG RESISTANCE PROTEIN 2; NER; NUCLEOTIDE EXCISION REPAIR; OS; OVARIAN CANCER; OVERALL SURVIVAL; PARP; PHOSPHATASE AND TENSIN HOMOLOG; POLY ADP RIBOSE POLYMERASE; PTEN; RELAPSE-FREE SURVIVAL; RESISTANCE; RFS; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; STIC; V-KI-RAS2 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG; V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; OVARY;

EID: 84892508265     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.08.017     Document Type: Review

References (58)

1. Buys S.S., Partridge E., Black A., et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011, 305:2295-2303.
2. Cannistra S.A. Cancer of the ovary. N Engl J Med 2004, 351:2519-2529.
3. Colombo N., Peiretti M., Parma G., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v23-v30.
4. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
5. du Bois A., Luck H.J., Meier W., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95:1320-1329.
6. Perren T.J., Swart A.M., Pfisterer J., et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
7. Burger R.A., Brady M.F., Bookman M.A., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
8. Monk B.J., Dalton H., Farley J.H., Chase D.M., Benjamin I. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol 2013, 86:161-175.
9. Vergote I., Trope C.G., Amant F., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2011, 363:943-953.
10. Friedlander M., Trimble E., Tinker A., et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011, 21:771-775.
11. Winter W.E., Maxwell G.L., Tian C., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:3621-3627.
12. Levanon K., Crum C., Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008, 26:5284-5293.
13. Hiss D. Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol 2012, 2012:737981.
14. Cho K.R., Shih Ie M. Ovarian cancer. Annu Rev Pathol 2009, 4:287-313.
15. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012, 460:237-249.
16. Alexandre J., Ray-Coquard I., Selle F., et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol 2010, 21:2377-2381.
17. Singer G., Kurman R.J., Chang H.W., Cho S.K., Shih Ie M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002, 160:1223-1228.
18. Crum C.P. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol 2009, 3:165-170.
19. Kurman R.J., Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34:433-443.
20. Kurman R.J., Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008, 27:151-160.
21. Chene G., Penault-Llorca F., Le Bouedec G., et al. Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk. Int J Gynecol Cancer 2009, 19:65-72.
22. Sato N., Tsunoda H., Nishida M., et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000, 60:7052-7056.
23. Wiegand K.C., Shah S.P., Al-Agha O.M., et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010, 363:1532-1543.
24. Katagiri A., Nakayama K., Rahman M.T., et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 2011, 25:282-288.
25. Takano M., Tsuda H., Sugiyama T. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?. J Exp Clin Cancer Res 2012, 31:53.
26. ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT01081262.
27. Hoskins P.J., Le N., Gilks B., et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol 2012, 30:1656-1662.
28. Colombo N., Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 2007, 64:129-138.
29. Ledermann J.A., Kristeleit R.S. Optimal treatment for relapsing ovarian cancer. Ann Oncol 2010, 21:vii218-vii222. Suppl 7.
30. Aghajanian C., Blank S.V., Goff B.A., et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30:2039-2045.
31. Pujade-Lauraine E., Hilpert F., Weber B., et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012, 30. [suppl; abstr LBA5002].
32. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001, 27:247-254.
33. Galluzzi L., Vitale I., Senovilla L., et al. Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle 2012, 11:3472-3480.
34. Borst P., Rottenberg S., Jonkers J. How do real tumors become resistant to cisplatin?. Cell Cycle 2008, 7:1353-1359.
35. Haslehurst A.M., Koti M., Dharsee M., et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012, 12:91.
36. Michels J., Vitale I., Galluzzi L., et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013, 73:2271-2280.
37. Smith S., Su D., Rigault de la Longrais I.A., et al. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol 2007, 25:5172-5179.
38. Krivak T.C., Darcy K.M., Tian C., et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 2008, 26:3598-3606.
39. Rubatt J.M., Darcy K.M., Tian C., et al. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Gynecol Oncol 2012, 125:421-426.
40. Friboulet L., Olaussen K.A., Pignon J.P., et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013, 368:1101-1110.
41. Bell D.B.A., Birrer M., Chien J., et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
42. Bolton K.L., Chenevix-Trench G., Goh C., et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012, 307:382-390.
43. Alsop K., Fereday S., Meldrum C., et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012, 30:2654-2663.
44. Yang D., Khan S., Sun Y., et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011, 306:1557-1565.
45. Dedes K.J., Wilkerson P.M., Wetterskog D., Weigelt B., Ashworth A., Reis-Filho J.S. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011, 10:1192-1199.
46. Sakai W., Swisher E.M., Karlan B.Y., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451:1116-1120.
47. Edwards S.L., Brough R., Lord C.J., et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451:1111-1115.
48. Norquist B., Wurz K.A., Pennil C.C., et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011, 29:3008-3015.
49. Heinrich M.C., Maki R.G., Corless C.L., et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008, 26:5352-5359.
50. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
51. Konstantinopoulos P.A., Spentzos D., Karlan B.Y., et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010, 28:3555-3561.
52. Ledermann J., Harter P., Gourley C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012, 366:1382-1392.
53. Etemadmoghadam D., deFazio A., Beroukhim R., et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 2009, 15:1417-1427.
54. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
55. Cooke S.L., Brenton J.D. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 2011, 12:1169-1174.
56. Eisenkop S.M., Friedman R.L., Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998, 69:103-108.
57. Colombo P.E., Mourregot A., Fabbro M., et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 2009, 35:135-143.
58. Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006, 103:1070-1076.